Invention Grant
- Patent Title: Bromodomain inhibitors
-
Application No.: US15436340Application Date: 2017-02-17
-
Publication No.: US10023592B2Publication Date: 2018-07-17
- Inventor: Amogh Boloor
- Applicant: Celgene Quanticel Research, Inc.
- Applicant Address: US CA San Diego
- Assignee: Celgene Quanticel Research, Inc.
- Current Assignee: Celgene Quanticel Research, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Wiley & Rein LLP
- Main IPC: C07D401/04
- IPC: C07D401/04 ; A61K31/44 ; A61K31/47 ; A61K31/505 ; C07D498/04 ; C07D217/24 ; C07D413/04 ; C07D471/04 ; C07D405/04 ; C07D213/64 ; C07D241/20 ; C07D213/73 ; C07D213/74 ; C07D487/04 ; C07D237/14 ; C07D401/14 ; C07D417/14 ; C07D405/12 ; C07D409/04 ; C07D405/06 ; C07D413/06 ; C07D491/048 ; C07D495/04 ; C07D401/12 ; C07D213/69 ; C07D213/70
Abstract:
The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
Public/Granted literature
- US20170158709A1 BROMODOMAIN INHIBITORS Public/Granted day:2017-06-08
Information query
